Inquiry Basket
Catalog | Product Name | CAS Number |
---|---|---|
BADC-00738 | MA-PEG4-VA-PBD | 1342820-68-1 |
MA-PEG4-VA-PBD is a drug-linker conjugate for ADC by using PBD (Pyrrolobenzodiazepine dimers, a potent antitumor antibiotic), linked via MA-PEG4-VA. | Inquiry | |
BADC-00751 | DBCO-PEG4-MMAF | 2360411-65-8 |
DBCO-PEG4-MMAF is a drug-linker conjugate for ADC by using Monomethylauristatin F (MMAF,a potent tubulin polymerization inhibitor), linked via DBCO-PEG4. | Inquiry | |
BADC-00771 | Thailanstatin B | |
a Pre-mRNA splicing inhibitor. Thailanstatin B is used as a cytotoxin for ADCs. | Inquiry | |
BADC-00772 | Thailanstatin C | |
a Pre-mRNA splicing inhibitor. Thailanstatin C is used as a cytotoxin for ADCs. | Inquiry | |
BADC-00773 | Thailanstatin D | |
a Pre-mRNA splicing inhibitor. The direct precursor of Thailanstatin A. Thailanstatin D is used as a cytotoxin for ADCs. | Inquiry | |
BADC-00774 | Fr901463 | |
a potent cell cycle inhibitor. Fr901463 exhibited potent antitumor activities against tumor cell lines via binding to the spliceosome and modulating pre-mRNA splicing. | Inquiry | |
BADC-00777 | Meayamycin | |
a potent pre-mRNA splicing inhibitor. Meayamycin modulates or inhibits splicing by targeting SF3B1. | Inquiry | |
BADC-00778 | Pladienolide B | 445493-23-2 |
a potent pre-mRNA splicing inhibitor. Pladienolide B has shown strong inhibitory effect against activity and growth of various cell lines via targeting SF3b. | Inquiry | |
BADC-00779 | Pladienolide D | |
a potent pre-mRNA splicing inhibitor. Pladienolide D has shown strong antitumor activity via targeting SF3b. | Inquiry | |
BADC-00781 | Spliceostatin B | |
a potent pre-mRNA splicing inhibitor. Spliceostatin B, an analog of FR901464, shows a weaker cytotoxic effect in cancer cells than FR901464. | Inquiry | |
BADC-00782 | Spliceostatin C | |
a potent pre-mRNA splicing inhibitor. Spliceostatin C is an analog of the natural product FR901464 and has shown a potent inhibit activity of eukaryotic RNA splicing via binding to SF3b. | Inquiry | |
BADC-00783 | Sudemycin C | |
a potent pre-mRNA splicing inhibitor. Sudemycin C has a potent inhibit activity of eukaryotic RNA splicing via binding to SF3b. | Inquiry | |
BADC-00785 | Sudemycin E | 1197054-49-1 |
a potent pre-mRNA splicing inhibitor. Sudemycin E is an analog of the natural product FR901464 and show a potent inhibit activity of cancer cell lines. | Inquiry | |
BADC-00786 | Sudemycin E0 | |
a potent pre-mRNA splicing inhibitor. Sudemycin E0 is an analog of the natural product FR901464 and shows a potent inhibit activity of cancer cell lines. | Inquiry | |
BADC-00787 | Sudemycin F1 | |
a potent pre-mRNA splicing inhibitor. Sudemycin F1 is an analog of the natural product FR901464 and shows a potent inhibit activity of cancer cell lines. | Inquiry | |
BADC-00792 | Illudin M | 1146-04-9 |
Illudin M is a natural sesquiterpene agent with strong anti-tumour activity. | Inquiry | |
BADC-00793 | PDM3 | |
20-O-Deme-thylansamitocin P-3 (PDM3),an ansamacrolide and maytansine analogue, has a greater antitumor activities against P388 and L 1210 than AP3. | Inquiry | |
BADC-00794 | Esperamicin | |
Esperamicinis an antitumor antibiotics, which combines the structural features of the anthracyclines and the enediynes. Esperamicinis are extremely toxic DNA splicing compounds and exhibits highly potent antitumor activity. | Inquiry | |
BADC-00795 | Anthramcyin | |
Anthramycin is a class of Pyrrolobenzodiazepines (PBDs)that shows antibacterial and potent antitumor activity. Anthramycin works by selectively inhibiting the synthesis of RNA and DNA of carcinoma cells. | Inquiry | |
BADC-00796 | Sibiromycin | 12684-33-2 |
It is an aminoglycoside antibiotic produced by the strain of Streptosporangium sibiricum. It has anti-bacterial effect and has an inhibitory effect on reticuloendothelial sarcoma RAB-1 and oncogenic AK/LY cells. Two times of the maximum tolerated dose of intravenous administration can inhibit OZH-5 tumor and lymphosarcoma Lic-1. It has very high DNA binding affinity and cytotoxicity against cancer cell lines. | Inquiry |